Metabolism and Pharmacokinetics of SP-8356, a Novel (1S)-(-)-Verbenone Derivative, in Rats and Dogs and Its Implications in Humans
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Zhou, Yuanyuan | - |
dc.contributor.author | Oh, Mun Hwan | - |
dc.contributor.author | Kim, Yeon Joon | - |
dc.contributor.author | Kim, Eun-yeong | - |
dc.contributor.author | Kang, Jinhong | - |
dc.contributor.author | Chung, Sung | - |
dc.contributor.author | Ju, Chung | - |
dc.contributor.author | Kim, Won-Ki | - |
dc.contributor.author | Lee, Kiho | - |
dc.date.accessioned | 2021-08-31T04:33:00Z | - |
dc.date.available | 2021-08-31T04:33:00Z | - |
dc.date.created | 2021-06-18 | - |
dc.date.issued | 2020-04-02 | - |
dc.identifier.issn | 1420-3049 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/56660 | - |
dc.description.abstract | (1S,5R)-4-((E)-3,4-dihydroxy-5-methoxystryryl)-6,6-dimethylbicylco[3.1.1]hept-3-en-2-one (SP-8356) is a novel (1S)-(-)-verbenone derivative that is currently in preclinical development for the treatment of ischemic stroke and atherosclerosis. This report aimed at characterization of the metabolism and pharmacokinetic properties of SP-8356. Following intravenous dose in rats and dogs, plasma concentrations of SP-8356 declined rapidly with high clearance (CL) and short half-life; after oral administration in both species, its plasma levels were below the quantitation limit. Fourteen circulating metabolites, formed by mono-oxygenation, demethylation, glucuronidation, catechol O-methylation, sulfation and oxidation (bioactivation) followed by glutathione (GSH) conjugation, were tentatively identified in both species. Urinary excretion of SP-8356 appeared to be minimal in rats, compared to its metabolites. GSH conjugate of SP-8356 was also formed during incubation with rat liver S9 fraction consistent with oxidative bioactivation; this bioactivation was almost completely inhibited by the cofactors for glucuronidation, sulfation and methylation, indicating that it may be abolished by competing metabolic reactions in the body. The human pharmacokinetics of SP-8356 was predicted to be similar to that of the animals based on the current in vitro metabolic stability results. In summary, rapid phase II metabolism appears to be mainly responsible for its suboptimal pharmacokinetics, such as high CL and low oral absorption. Because of competing metabolic reactions, potential safety risks related to SP-8356 bioactivation may be low. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | MDPI | - |
dc.subject | DRUG DISCOVERY | - |
dc.subject | BIOLOGICAL-ACTIVITY | - |
dc.subject | SMALL-INTESTINE | - |
dc.subject | ESSENTIAL OIL | - |
dc.subject | IN-VITRO | - |
dc.subject | CONJUGATION | - |
dc.subject | SULFATION | - |
dc.subject | BIOACTIVATION | - |
dc.subject | DECONJUGATION | - |
dc.subject | ROLES | - |
dc.title | Metabolism and Pharmacokinetics of SP-8356, a Novel (1S)-(-)-Verbenone Derivative, in Rats and Dogs and Its Implications in Humans | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Won-Ki | - |
dc.contributor.affiliatedAuthor | Lee, Kiho | - |
dc.identifier.doi | 10.3390/molecules25081775 | - |
dc.identifier.scopusid | 2-s2.0-85083457006 | - |
dc.identifier.wosid | 000534617300009 | - |
dc.identifier.bibliographicCitation | MOLECULES, v.25, no.8 | - |
dc.relation.isPartOf | MOLECULES | - |
dc.citation.title | MOLECULES | - |
dc.citation.volume | 25 | - |
dc.citation.number | 8 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Biochemistry & Molecular Biology | - |
dc.relation.journalResearchArea | Chemistry | - |
dc.relation.journalWebOfScienceCategory | Biochemistry & Molecular Biology | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Multidisciplinary | - |
dc.subject.keywordPlus | DRUG DISCOVERY | - |
dc.subject.keywordPlus | BIOLOGICAL-ACTIVITY | - |
dc.subject.keywordPlus | SMALL-INTESTINE | - |
dc.subject.keywordPlus | ESSENTIAL OIL | - |
dc.subject.keywordPlus | IN-VITRO | - |
dc.subject.keywordPlus | CONJUGATION | - |
dc.subject.keywordPlus | SULFATION | - |
dc.subject.keywordPlus | BIOACTIVATION | - |
dc.subject.keywordPlus | DECONJUGATION | - |
dc.subject.keywordPlus | ROLES | - |
dc.subject.keywordAuthor | SP-8356 | - |
dc.subject.keywordAuthor | pharmacokinetics | - |
dc.subject.keywordAuthor | metabolism | - |
dc.subject.keywordAuthor | bioactivation | - |
dc.subject.keywordAuthor | conjugation | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
145 Anam-ro, Seongbuk-gu, Seoul, 02841, Korea+82-2-3290-2963
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.